EXELIXIS EVIDENCE LOG
Updated September 16, 2026 | Yenra
Guide: https://yenra.com/biotechn/exelixis.html

Purpose: separate product, trial, regulatory and business claims.
Use one record per claim. Copy the exact document date and keep the URL.
Write unknown rather than inferring a missing result or approved use.
This is an information-review aid, not a treatment or investment recommendation.

CLAIM RECORD
Date checked:
Source date, title and URL:
Exact claim, in your own words:
Molecule, development code, brand and formulation:
Regimen/combination partner:
Country or regulator:
Cancer type, stage, prior treatment and other population criteria:
Evidence category: preclinical / trial / regulatory / business / forecast.

IF A TRIAL
Registry identifier and last update:
Comparator and eligibility:
Primary endpoint and analysis population:
Effect estimate, units, confidence interval and follow-up:
Adverse events and discontinuations:
Other endpoints/subgroups and their status:
Publication, registry results and corrections:

IF REGULATORY
Submission, acceptance for review, decision or label change:
Actual decision date and exact indication, if available:
Current label link and revision date:
Unresolved next step:

IF BUSINESS
Reporting period and filing:
Product sales, royalties or collaboration payments involved:
Territory and relevant partner:
Risks, dependencies and differences between results and forecasts:

DATED EXAMPLE TO VERIFY BEFORE REUSE
On August 5, 2026, Exelixis reported ongoing FDA review of zanzalintinib
with atezolizumab for previously treated metastatic colorectal cancer.
Reported target action: December 3, 2026. Trial: NCT05425940.
Record any later decision and exact label separately.
Source: https://ir.exelixis.com/static-files/fe809677-bfbd-42c6-8538-73244509c5b7

CURRENT LOOKUPS
Medicines and label links: https://www.exelixis.com/medicines/
Pipeline: https://www.exelixis.com/clinical-trials-pipeline/
Trial: https://clinicaltrials.gov/study/NCT05425940
Annual reports: https://ir.exelixis.com/financials/annual-reports

FOLLOW-UP
What remains uncertain:
Source needed to resolve it:
Event that should trigger a recheck: